论文部分内容阅读
Objective: The efficacy of preoperative transarterial chemoembolization(TACE) for hepatectomy on hepatocelluar carcinoma(HCC) is still controversial. This study aims to evaluate the efficacy of preoperative TACE on resectable HCC. Methods: Pubmed, SCI, Medline, EMBASE, Cochrane Datebase, CNKI were searched. The articles that focused on preoperative TACE for resectable HCC, published from 1990 to 2012, were collected by computerized search of literatures and manual search of bibliographies. The relevant clinical trials’ data were reviewed by meta-analysis using the random effects model or fixed effect model by heterogeneity. The outcomes were expressed as odds ratio(OR) with 95% confidence intervals(CIs). Results: A total of 1347 patients were included in these 7 studies, the cases were divided into the preoperative TACE group and the non-preoperative TACE group, and there was no difference between the two groups in the 3-year disease-free survival rate, with an odds ratio of 1.14(95% CI = 0.90–1.45, P = 0.27); the 5-year disease-free survival rate in the preoperative TACE group was better than that in the non-TACE group with an odds ratio of 1.35(95% CI = 1.07–1.74, P = 0.02); the 5-year overall survival rate in the preoperative TACE group was higher than that in the non-TACE group with an odds ratio of 0.59(95% CI = 0.46–0.77, P < 0.0001). Conclusion: The present data suggests that preoperative TACE has no different in improving the 3-year disease-free survival rate with non-TACE group for resectable HCC, while it can improve the 5-year disease-free survival rate and the 5-year overall survival rate. More randomized controlled trials using large sample size are needed to provide sufficient evidence to confirm current conclusion.
Objective: The efficacy of preoperative transarterial chemoembolization (TACE) for hepatectomy on hepatocelluar carcinoma (HCC) is still controversial. This research aims to evaluate the efficacy of preoperative TACE on resectable HCC. Methods: Pubmed, SCI, Medline, EMBASE, Cochrane Datebase, The articles that focused on preoperative TACE for resectable HCC, published from 1990 to 2012, were collected by computerized search of literatures and manual search of bibliographies. The relevant clinical trials’ data were reviewed by meta-analysis using the random effects The results were expressed as odds ratio (OR) with 95% confidence intervals (CIs). Results: A total of 1347 patients were included in these 7 studies, the cases were divided into the preoperative TACE group and the non-preoperative TACE group, and there was no difference between the two groups in the 3-year disease-free survival rate, with an odds ratio of 1.14 (95% C I = 0.90-1.45, P = 0.27); the 5-year disease-free survival rate in the preoperative TACE group was better than that in the non-TACE group with an odds ratio of 1.35 (95% CI = 1.07-1.74, P = 0.02); the 5-year overall survival rate in the preoperative TACE group was higher than that in the non-TACE group with an odds ratio of 0.59 (95% CI = 0.46-0.77, P <0.0001). Conclusion: The present data suggests that preoperative TACE has no different in improving the 3-year disease-free survival rate with non-TACE group for resectable HCC, while it can improve the 5-year disease-free survival rate and the 5-year overall survival rate More randomized controlled trials using large sample size are needed to provide sufficient evidence to confirm current conclusion.